Abstract 2994
Background
Antiangiogenic therapy in combination with chemotherapy has shown improved clinical benefit in advanced cancer. In third-line therapy, apatinib(a TKI against VEGFR-2) has shown good safety and efficacy for advanced gastric cancer. However, the safety and efficacy of apatinib combined with docetaxel in second-line treatment of advanced gastric cancer remains unclear.
Methods
From Mar 2017 to Dec 2018, 40 patients with advanced gastric cancer after failure of first-line chemotherapy were enrolled in this open-lable, prospective study. All patients were treated by apatinib (500mg, qd) with docetaxel (60mg/m2,d1, q21d). According to the docetaxel course of treatment, study treatment was continued as a 21-day cycle. After 6 cycles, apatinib alone maintenance. Efficacy was evaluated every 2 cycle based on RECIST version 1.1. The primary endpoint was progression-free survival (PFS). The secondary endpoints were objective response rate (ORR), disease control rate (DCR), overall survival (OS), safety and quality of life.
Results
Forty enrolled patients baseline characteristics are shown in the table below. The partial response (PR) 5 cases, stable disease rat (SD) 27 cases, and progression disease (PD) 8 cases. The median PFS 4.6 months. The ORR and DCR were 12.5% and 80.0%, respectively. During the treatment period, a patient with multiple hepatic metastases of gastric antral adenocarcinoma received 6 cycles of apatinib combined with docetaxel and sustained by apatinib alone. The disease-free survival time was 10.4 months.The main adverse reactions in this study were hypertension (67.5%, n = 27), proteinuria (30.0%, n = 14), bone marrow depression (22.5%, n = 9), fecal occult blood (7.5%, n = 3). The adverse reactions in the course of treatment were controlled after symptomatic treatment, and most of them did not affect normal activities.
Conclusions
In the second-line treatment for patients with advanced gastric cancer, apatinib combined with docetaxel exhibits superior activity. Moreover, the toxicities were tolerable and could be clinically managed.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
China Anti-Cancer Association, Chinese Society of Clinical Oncology.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
3905 - Loss of CDX-2 expression is an independent poor prognostic biomarker in colorectal cancer
Presenter: Krittiya Korphaisarn
Session: Poster Display session 2
Resources:
Abstract
3963 - Robot-assisted natural orifice specimen extraction surgery for radical resection of colorectal cancer
Presenter: Zhengchuan Niu
Session: Poster Display session 2
Resources:
Abstract
3989 - Bevacizumab as adjuvant treatment for colon cancer: Updated results from the AVANT phase III Study by the GERCOR Group
Presenter: Thierry André
Session: Poster Display session 2
Resources:
Abstract
4741 - Real world data on adjuvant chemotherapy for high-risk stage II colorectal cancer – the role of tumor side
Presenter: Camila Araujo de Carvalho
Session: Poster Display session 2
Resources:
Abstract
4973 - Oncological Outcome and Safety of Bevacizumab (BV) Therapy in Patients with Occlusive Colon Cancer and Self-Expandable Metal Stents (SEMS)
Presenter: Vilma Pacheco-Barcia
Session: Poster Display session 2
Resources:
Abstract
2295 - Active chronic hepatitis B increases the risk of liver metastasis of colorectal cancer- a retrospective clinical study of 7187 consecutive cases of newly diagnosed colorectal cancer
Presenter: Lei Zhao
Session: Poster Display session 2
Resources:
Abstract
3845 - Comprehensive Evaluation of Recurrence Risk (CERR) Score for Colorectal Liver Metastases: Development and Validation
Presenter: Wei Ye
Session: Poster Display session 2
Resources:
Abstract
1976 - BRAF-mutated colorectal metastases: what is the benefit of liver surgery? Results from a cohort of 91 patients.
Presenter: Sahir Javed
Session: Poster Display session 2
Resources:
Abstract
2688 - The smallest colorectal liver metastasis size as a prognosis factor after laparoscopic liver resection
Presenter: Baptiste Cervantes
Session: Poster Display session 2
Resources:
Abstract
4961 - Validation of GAME score risk groups in resected colorectal cancer liver metastases and the prognostic relevance of KRAS, NRAS and BRAF mutation analysis
Presenter: Berta Martin-Cullell
Session: Poster Display session 2
Resources:
Abstract